iosBio appoints Patricia Londono-Hayes as Chief Improvement Officer
Oral vaccines and biotherapeutics firm strengthens senior management group with new function to drive precedence improvement programmes
Burgess Hill, UK, 14 June 2021—iosBio (‘the Firm’), a UK-based biotechnology firm growing next-generation vaccines that may be administered orally, immediately declares the appointment of Patricia Londono-Hayes, PhD, as Chief Improvement Officer.
With greater than 20 years of expertise within the pharmaceutical and biotechnology sector, Patricia is a pacesetter in vaccines and biologics product improvement. She brings intensive expertise within the development of vaccine candidates from preliminary idea into first-in-human testing, development of medical improvement and licensing.
In her function, Patricia will lead the event and execution of iosBio’s pipeline technique, because the Firm strikes into its subsequent stage of development. In January 2021 iosBio signed an unique worldwide licensing settlement granting ImmunityBio rights to its OraPro™ vaccine platform expertise for the oral supply of ImmunityBio’s second-generation human Adeno (hAd5) COVID-19 vaccine candidate. iosBio’s second precedence programme, OraPro-Flu – a thermally steady, orally-delivered, quadrivalent seasonal influenza vaccine – is presently in preclinical research and anticipated to enter the clinic later this yr.
Throughout her profession, Patricia has directed international programmes, groups, and partnerships at scientific, strategic, and operational ranges, contributing to the event and licensing of vaccines spanning a broad vary of indications together with influenza and a wide range of respiratory, gastro-intestinal, genito-urinary, and nosocomial infections.
Patricia joins iosBio from Sanofi Pasteur, the place she held positions of accelerating accountability, most just lately as Head of Exterior R&D Initiatives and Scientific Affairs, Europe, the place she led the technique and implementation of exterior R&D public‐non-public partnerships and alliances. Throughout her tenure, she spearheaded multi million Euro investments in R&D partnerships between the corporate and different vaccine producers, main educational establishments, the EU and the Gates Basis. Previous to that, she was Head of International Preclinical Analysis & Improvement Division and Chief of the Common Influenza Vaccine Undertaking on the firm, overseeing, translational, preclinical, and medical pharmacology analysis. Earlier than becoming a member of Sanofi Pasteur, Patricia labored at vaccine firm Acambis, the place she based and directed the Immunology Analysis Division and initiated analysis applications in oral vaccines.
She gained her PhD in Biochemistry and Immunology from Imperial School London and holds an MSc in Molecular Biology and Genetic Manipulation and a BSc in Microbiology from the College of Sussex and College of Los Andes, respectively.
Government Chairman of iosBio, Wayne Channon mentioned: “With her spectacular observe report in vaccine improvement, I’m delighted to welcome Patricia to iosBio. Her breadth of expertise in main vaccines programmes from concept by way of to medical improvement will likely be crucial as we pursue our mission to lead the best way in subsequent era, oral vaccines.”
Patricia Londono-Hayes commented: “I’m thrilled to be becoming a member of iosBio at such an thrilling stage, with the Firm’s OraPro™ vaccine platform expertise being investigated in trials of what may very well be the primary oral COVID-19 vaccine. iosBio’s science has the potential to really rework vaccine improvement and to beat the worldwide challenges of conventional vaccines. I’m delighted to be becoming a member of such an skilled and progressive group and stay up for working together on IosBio’s imaginative and prescient to deliver orally administered, thermally steady vaccines to individuals world wide.”
For further data please contact:
Consilium Strategic Communications
Mary-Jane Elliott, Melissa Gardiner, David Daley
Tel: +44 (0) 20 3709 5700
NOTES FOR EDITORS
iosBio is a UK based mostly biotechnology firm growing subsequent era vaccines that may be administered orally.
The Firm’s proprietary OraPro™ thermal stabilization expertise allows the oral administration of thermally steady, non-replicating viral vectors that may be delivered sublingually through the gastrointestinal (GI) tract and different routes. These vaccine vectors are engineered to resist temperatures of as much as 50 levels and the hostile circumstances within the abdomen with out lack of efficacy and offering long run product stability at ambient temperatures.
iosBio is growing vaccines designed to stimulate mucosal, systemic and T cell immune responses, offering strong immunity to various infectious illnesses together with COVID-19, Zika and influenza.
In January 2021 iosBio introduced an unique worldwide licensing settlement with ImmunityBio, Inc. a US-based, privately held clinical-stage immunotherapy firm, for iosBio’s OraPro™ vaccine platform expertise presently being investigated in a Section Ib trial of ImmunityBio’s second-generation human Adeno (hAd5) COVID-19 vaccine candidate.
iosBio is headquartered in Burgess Hill, UK. For extra data go to: iosbio.com